OMC
ADVM

Oasis Management Company’s Adverum Biotechnologies ADVM Stock Holding History

Oasis Management Company’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-46,500
Closed -$269K – 79
2022
Q4 		$269K Hold
46,500
– – 0.05% 87
2022
Q3 		$442K Hold
46,500
– – 0.07% 90
2022
Q2 		$558K Buy
+46,500
New +$487K 0.1% 82

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Oasis Management Company's ADVM Position: Q1 2023 in Review

Oasis Management Company sold out of Adverum Biotechnologies (ADVM) in Q1 2023, closing a stake of 46,500 shares — an estimated $269K sold.

Oasis Management Company first reported a position in ADVM in Q2 2022 and held it in 3 quarters. The position peaked at $558K in Q2 2022. 55 funds tracked by Wall St. Rank hold ADVM as of Q1 2023.

  • Oasis Management Company reported no remaining Adverum Biotechnologies position as of Q1 2023 after selling out during the quarter.
  • Oasis Management Company sold 46,500 Adverum Biotechnologies shares in Q1 2023, an estimated $269K.
  • Oasis Management Company first reported a position in Adverum Biotechnologies in Q2 2022 and held it in 3 quarters.
  • Oasis Management Company's Adverum Biotechnologies position peaked at $558K in Q2 2022.
  • 55 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q1 2023.

Based on Oasis Management Company's 13F filing for Q1 2023, filed 15 May 2023.